AQST
Aquestive Therapeutics Inc
NASDAQ: AQST · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$4.10
+1.23% today
Updated 2026-04-30
Market cap
$509.57M
P/E ratio
—
P/S ratio
11.44x
EPS (TTM)
$-0.78
Dividend yield
—
52W range
$2 – $8
Volume
1.7M
Aquestive Therapeutics Inc (AQST) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-188.10%
Operating margin
-221.60%
ROE
0.00%
ROA
-33.90%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2005 | $2.12M | $-8.28M | 39.61% | -366.89% | -390.16% |
| 2006 | $2.71M | $-12.75M | 40.22% | -449.24% | -469.69% |
| 2016 | $51.78M | $-9.60M | 68.37% | -1.64% | -18.54% |
| 2017 | $66.92M | $-8.94M | 70.38% | -0.17% | -13.36% |
| 2018 | $67.43M | $-61.38M | 68.87% | -72.57% | -91.02% |
| 2019 | $52.61M | $-66.25M | 61.30% | -100.11% | -125.92% |
| 2020 | $45.85M | $-55.78M | 71.72% | -93.55% | -121.67% |
| 2021 | $50.83M | $-70.54M | 70.51% | -68.22% | -138.77% |
| 2022 | $47.68M | $-54.41M | 59.34% | -88.23% | -114.11% |
| 2023 | $50.58M | $-7.87M | 58.82% | -29.86% | -15.56% |
| 2024 | $57.56M | $-44.14M | 68.95% | -53.46% | -76.68% |
| 2025 | $44.55M | $-83.78M | 58.35% | -159.50% | -188.09% |